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ABSTRACT
The Hippo pathway, which acts to repress the activity of YAP and TAZ 
trancriptional co-activators, serve as a barrier for oncogenic transformation. Unlike 
other oncoproteins, YAP and TAZ are rarely activated by mutations or amplified in 
cancer. However, elevated YAP/TAZ activity is frequently observed in cancer and 
often correlates with worse survival. The activity and stability of Hippo pathway 
components, including YAP/TAZ, AMOT and LATS1/2, are regulated by ubiquitin-
mediated protein degradation. Aberrant expression of ubiquitin ligase complexes 
that regulate the turnover of Hippo components and deubiquitylating enzymes that 
counteract these ubiquitin ligases have been implicated in human cancer. Here we 
identify the USP21 deubiquitylating enzyme as a novel regulator of Hippo pathway 
activity. We provide evidence that USP21 regulates YAP/TAZ activity by controlling 
the stability of MARK kinases, which promote Hippo signaling. Low expression of 
USP21 in early stage renal clear cell carcinoma suggests that USP21 may be a useful 
biomarker.
INTRODUCTION
The Hippo pathway has emerged as a major barrier 
for oncogenic transformation [1]. Hippo signaling 
represses the activity of the transcriptional co-activators 
YAP and TAZ, so that loss of pathway activity leads to 
increased YAP/TAZ activity. Previous studies have shown 
that expression or activity of Hippo pathway components 
are frequently suppressed in cancer, similar to other 
key tumor suppressor pathways such as PTEN, p14ARF/
p53 and p16/pRb (reviewed in [2]). NF2, a promoter of 
Hippo signaling is the Hippo pathway component most 
often inactivated by mutation, as reported in the COSMIC 
database (reviewed in [2]) and its loss is associated with a 
heritable cancer syndrome [3]. Inactivation of other Hippo 
genes such as RASSF1A, FAT1-4, RASSF2, RASSF4 
through mutation or silencing was also observed in cancer 
(reviewed in [2, 4]). Similarly, increased YAP/TAZ 
expression or an increase in their activity has frequently 
been documented in comprehensive surveys of solid-
tumor cancers, including lung, colorectal, pancreatic, 
hepatocellular, ovarian, and prostate carcinomas [5–8]. 
Tumors with high YAP activity often correlate with worse 
cancer survival [9–12]. Interestingly, elevated YAP or 
TAZ activity also confers tumor cells with the ability to 
evade anti-cancer drugs. Using synthetic lethality screens 
or RNAi approaches, two groups have recently reported 
that activated YAP made B-Raf mutant or Ras-harboring 
tumor cells resistant to MEK-targeted cancer therapies 
[13, 14]. Together, these studies have shed light on the 
importance of Hippo deregulation in cancer development 
and suggest that the Hippo pathway may play a key role 
in the acquisition of drug resistance. Further studies on 
the mechanisms of Hippo pathway regulation and its 
deregulation in cancer will be important in suggesting new 
avenues of therapeutic approach.
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Several lines of evidence suggest that regulation 
of Hippo pathway proteins through ubiquitin-mediated 
degradation plays an important role in human cancer. 
The core Hippo pathway kinases, mammalian sterile-
20-like (MST1/2) and large tumor suppressor kinase 1/2 
(LATS1/2), phosphorylate the YAP and Taz proteins and 
prevent them from exerting their roles as transcriptional 
co-activators that promote carcinogenesis. Phosphorylated 
YAP and TAZ are targeted by the bTrCP/SCF ubiquitin 
ligase system for degradation [15, 16]. YAP protein 
turnover is regulated by Ras signaling, through regulation 
of SOCS5/6 expression, which recruits YAP to an Elongin 
B/C-Cullin5 ubiquitin ligase complex [17]. While 
promoting the degradation of YAP and Taz is central to 
the effect of activated Hippo signaling, the ubiquitin-
mediated degradation process has been shown to occur at 
multiple nodes in the Hippo pathway to regulate YAP/Taz 
activity. The E3 ligase PRAJA2 promotes degradation of 
MOB1, an upstream regulator of LATS kinases, and has 
been shown to promote glioblastoma [18]. The NEDD4 
family of E3-ligase proteins have been shown to regulate 
the abundance of LATS kinases, AMOT and AMOT-
like proteins, which suppress YAP activity [19–21]. As a 
consequence, an increased expression of these E3 ligases 
is sufficient to promote tumorigenesis [22]. We recently 
reported that deubiquitylating (DUB) enzyme USP9X 
could act as a tumor suppressor by promoting the stability 
of AMOT proteins and suppressing YAP/TAZ activity. 
USP9X is under-expressed in many kidney tumors, 
where its expression level correlated with patient survival 
[23]. Another deubiquitylating enzyme, DUB3, was also 
reported to regulate YAP/TAZ activity by mediating the 
stability of multiple Hippo components, such as ITCH, 
LATS kinases and AMOT proteins [24].
Here we present evidence that the deubiquitylating 
enzyme USP21 controls YAP/TAZ activity indirectly, 
by regulating the stability of the MARK family protein 
kinases. USP21 deubiquitylates MARK proteins to 
control their stability. The MARK kinases in turn regulate 
LATS1/2 kinase activity and thereby regulate YAP/
Taz phosphorylation and stability. We provide evidence 
that USP21 limits anchorage-independent growth of 
transformed primary cells and cancer cell lines. USP21 
protein was expressed at low levels in a majority of renal 
clear cell carcinoma (RCC) samples, suggesting that low 
USP21 activity could increase cancer relevant cellular 
phenotypes.
RESULTS
USP21 mediates YAP activity
USP21 was identified in a shRNA screen for DUBs 
that regulate YAP/TAZ activity (ref [23]; the HGNC 
designation for this protein has been changed from USP23 
to USP21). Depletion of USP21 by two independent 
shRNAs or a pooled shRNA mixture significantly 
increased YAP reporter activity (Figure 1A) in HEK293T 
cells. These shRNAs efficiently reduced USP21 protein 
expression (Figure 1A). The effect of USP21 depletion 
was reproduced by using two independent siRNAs 
targeting USP21 (Figure 1B). These siRNAs strongly 
reduced USP21 mRNA levels, measured by qPCR (Figure 
1C), and led to a significant increase in expression of the 
YAP transcriptional targets, CTGF and Cyr61 (Figure 1C). 
We observed a similar effect of USP21 depletion in several 
other cell types. Stable expression of USP21 shRNAs led 
to increased CTGF and Cyr61 expression in BJ fibroblasts, 
lung carcinoma A549 cells and in metastatic breast cancer 
MDA-MB-231 cells (Supplementary Figure 1).
Overexpression of USP21 had the opposite effect, 
suppressing YAP reporter activity (Figure 1D). Expression 
of a catalytically inactive mutant form of USP21C221S [25] 
showed no inhibitory effect on YAP reporter activity 
(Figure 1D), although the USP21C221S mutant protein was 
expressed at a comparable level to the native protein. 
Instead, the USP21C221S mutant appeared to increase YAP 
reporter activity, perhaps suggesting a dominant negative 
effect; though we note that the effect was not strong 
enough to be statistically significant (p=0.07). These 
results suggest that the enzymatic activity of USP21 is 
required for its inhibitory effect on YAP activity.
Nuclear localization of YAP is often taken as an 
indicator of increased YAP activity. Nuclear localization 
of YAP increased significantly in BJ cells depleted 
of USP21, compared to the control cells (Figure 1E, 
Supplementary Figure 2), consistent with the observation 
that USP21 inhibition increased YAP reporter activity 
and transcriptional expression of YAP target genes. Taken 
together, these data indicate that USP21 regulates the 
transcriptional activity of YAP.
USP21 regulates MARK kinase stability
To examine how USP21 regulates YAP/TAZ 
activity, we examined the effects of USP21 depletion 
on the expression levels of Hippo pathway proteins. 
HEK293T cells were transfected to express shRNAs 
independently or in a pool targeting USP21. There was 
a strong increase in total protein levels of YAP and to a 
lesser extent of TAZ (Figure 2A). This was accompanied 
by reduced YAP phosphorylation at Ser127 and S397 
(Figure 2A), which are target sites of LATS kinases. 
Given that phosphorylation of these sites targets YAP 
and TAZ for degradation, the effect of USP21 depletion 
on YAP levels is likely a consequence of the reduced 
YAP turnover. Reduced phosphorylation could be due 
to reduced expression or activity of the LATS kinases. 
However, USP21 depletion did not change the level of 
LATS1 or LATS2 proteins. Instead, phosphorylation 
of LATS1/2 (Thr1079/1041) was strongly reduced 
(Figure 2B), indicating reduced LATS kinase activity. This 
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suggested that the effects of USP21 might be mediated via 
a kinase that phosphorylates the LATS proteins.
We next tested the effect of USP21 depletion on 
known regulators of LATS kinases, MST kinases and the 
LATS1/2 coactivator MOB1 (reviewed in [26]). Depletion 
of USP21 did not significantly change the phosphorylation 
of MOB1 or the level of total MOB1 protein (Figure 
2B). Total MST1 was also unaffected (Figure 2B, 
phosphorylated MST1/2 was not detected unless the cells 
were treated with phosphatase inhibitors, and so could not 
be assessed).
Microtubule affinity-regulating kinase (MARK) 
family proteins are serine/threonine kinases that were 
recently shown to serve as regulators of LATS1/2 kinases 
[27]. Importantly, in this context the MARK kinases act 
on LATS proteins independently of the MST kinases 
[27]. The MARK kinase family consists of 4 closely 
related proteins encoded by different loci [27, 28]. 
Figure 1: USP21 regulates YAP/TAZ activity. (A) Luciferase reporter assays showing USP21 shRNAs increases YAP/TAZ activity. 
HEK293T cells were co-transfected to express the YAP/TAZ reporters together with USP21 shRNAs or with a control vector. YAP/TAZ 
activity was calculated as a ratio of firefly to Renilla activity. Data were normalized to the relevant control and represent the mean of three 
independent transfection experiments ± SD. (B) Luciferase reporter assays showing YAP/TAZ activity. HEK293T cells were co-transfected 
with reporter plasmids together with USP21 siRNAs or with a control siRNA. Data represent the mean of three independent transfection 
experiments ± SD. (C) Quantitative PCR for the expression of YAP transcriptional targets. HEK293T cells were transfected to express a 
scrambled control or independent siRNAs targeting USP21. Data represent the average of 3 independent experiments ± SD. (D) Luciferase 
reporter assays showing YAP/TAZ activity. HEK293T cells were co-transfected to express the reporters together with a plasmid expressing 
USP21 wild type or mutant (C221S) or a control vector. Data represent the mean of three independent replicates ± SD. (E) YAP localization 
was scored as previously described [24]. Representative images are provided in Supplementary Figure 2. Data represent the average of 
three independent experiments ± SD.
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USP21 depletion reduced the expression of MARK1 and 
2 proteins (Figure 2C), but not the mRNA transcripts 
(Supplementary Figure 3A). USP21 depletion also led to 
reduced phosphorylation of the MARK activation loop. 
This may be due to the reduced level of MARK proteins 
in these cells. Conversely, overexpression of USP21, but 
not of the catalytically inactive C221S mutant, stabilized 
MARK1 and MARK2 protein expression (Supplementary 
Figure 3B). These observations indicate that USP21 
regulates the stability of the MARK family proteins.
To ask which of the MARK isoforms are involved in 
regulation of YAP activity, we depleted the MARK kinase 
family members individually and measured YAP reporter 
activity in HEK293T cells. qPCR analysis confirmed that 
the siRNAs selectively depleted their target transcripts in 
an efficient manner (Supplementary Figure 4A). Depletion 
of MARK3 had little or no effect on YAP reporter activity; 
MARK1 and 4 depletion increased YAP activity 2-5 fold; 
and depletion of MARK2 caused over a 20 fold increase 
(Supplementary Figure 4B). Next, we tested the effects of 
Figure 2: USP21 regulates the stability of MARK proteins and MARK1 ubiquitylation. (A-C) Immunoblots showing 
effects of USP21 depletion on Hippo pathway components in HEK293T cells. Blots were probed with the indicated antibodies. Anti-Actin 
was used to control for loading. Data in panels A-C are from the same blots, so the same anti-Actin controls were used. (D) Immunoblots 
showing co-immunoprecipitation of MARK1 and USP21. Lysates from MG132-treated HEK293T cells were immunoprecipitated with 
agarose-conjugated antibodies against USP21 or MARK1 or IgG control antibodies overnight. Separate blots were probed with antibodies 
against USP21 and MARK1. (E) Immunoblots of HEK293T cells co-transfected to express myc-MARK1 (or myc-MARK1K768A)/HA-
tagged ubiquitin and a scrambled or USP21-specific siRNA to deplete USP21 for 36h. Lysates were immunoprecipitated with anti-myc to 
recover MARK1 and blots were probed with anti-HA (for ubiquitin detection), anti-myc (MARK1), anti-USP21 and anti-Actin.
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USP21 depletion is cells co-depleted for MARK kinases 
using siRNAs specific to individual MARK kinases. 
Reducing MARK1, 2 levels attenuated the effect of USP21 
depletion on YAP activity, while MARK4 depletion has 
a more limited effect (Supplementary Figure 5). These 
observations provide evidence that all three MARK 
kinases contribute to mediating the effects of USP21 on 
YAP/TAZ activity.
All of the MARK protein isoforms have 
been shown to interact with USP21 in assays using 
overexpressed epitope-tagged proteins [29, 30]. We 
sought to examine whether USP21 could interact with 
MARK1 at endogenous levels. MARK1 was previously 
identified as a possible target for ubiquitylation [31], and 
so was expected to be unstable if USP21 was involved 
in deubiquitylating MARK proteins. For this reason, we 
treated HEK 293T cells with MG132 to limit proteasome-
mediated protein degradation prior to preparing lysates 
for immunoprecipitation (IP). Under these conditions, 
we observed co-IP of MARK1 when performing IP with 
antibody to USP21 (Figure 2D). Reciprocally, USP21 
was recovered in the anti-MARK1 IP (Figure 2D). These 
assays provide evidence for interaction of the endogenous 
proteins.
Next, we asked whether USP21 affects the 
ubiquitylation status of MARK1. As shown in Figure 
2E, USP21 depletion increased the amount of ubiquitin 
detected on MARK1 purified by IP. The peptide sequence 
SGTSIAFKNIASKIA from MARK1 containing lysine 
768 has been identified as a ubiquitylated substrate [31]. 
The K768A mutant form of MARK1 showed considerably 
less ubiquitylation following USP21 depletion than the 
wild type MARK1 protein (Figure 2E), suggesting that 
K768 is a site at which USP21 dequbiquitylates MARK1. 
Overexpression of USP21 significantly reduced ubiquitin 
incorporation into MARK1 but has less impact on the 
MARK1K768A mutant (Supplementary Figure 6). These 
findings suggest that USP21-mediated deubiquitylation 
regulates the stability of MARK1.
USP21 depletion enhances oncogenic 
transformation
Our findings thus far have shown that USP21 limits 
YAP/TAZ activity, through regulation of MARK kinase 
turnover. Given the importance of YAP/TAZ activity 
in cellular transformation, we wanted to ask whether 
USP21 might limit transformation through regulation of 
YAP/TAZ. To test this, we employed an assay based on 
anchorage-independent growth of partially transformed 
primary human fibroblasts (BJ fibroblast cells expressing 
shRNAs to deplete p53/p16 and activated RasG12V along 
with native YAP in place of the small t oncoprotein that 
is conventionally used along with RasG12V to transform 
primary cells to anchorage independence) [1]. We 
previously found that small t could be replaced by 
expression of a moderate level of native YAP protein, and 
that the amount of soft-agar colony formation in these 
assays was very sensitive to the amount of YAP activity 
[1]. As a control, we verified that depletion of LATS2 
kinase strongly increased soft agar colony formation in 
this experiment (Figure 3A and 3B). Expression of two 
independent shRNAs targeting USP21 also significantly 
increased colony formation (Figure 3A and 3B). USP21 
depletion also led to increased soft agar colony formation 
in A549 and MDA-MB-231 cancer cell lines (Figures 
3C and 4D: recall that YAP target gene expression was 
increased in these cancer cell lines following USP21 
depletion, Supplementary Figure 1). Thus, depletion 
of USP21 can increase YAP/TAZ activity and increase 
the ability of cells to grow in an anchorage independent 
manner. These findings suggest that USP21 could have 
tumor suppressive activity, mediated through regulation 
of YAP/TAZ.
USP21 expression in human cancer
Next, we sought to investigate the expression of 
USP21 protein in human cancer. An initial survey of 
data from ProteinAtlas.org suggests that USP21 protein 
is abundant in human uterine, gastric and kidney normal 
tissues, detected by immunohistochemical staining. 
Interestingly, USP21 expression was lost or reduced in 
all 12 reported cases of renal clear carcinomas (RCC), 
compared to adjacent normal tissues (http://www.
proteinatlas.org/ENSG00000143258-USP21/cancer).
Tissue microarrays provided access to a larger 
collection of RCC samples paired with normal 
kidney tissue from the same patients. We performed 
immunohistochemical labeling to investigate the protein 
expression of USP21 (Figure 4A) using the tested USP21 
antibody (HPA028397) recommended by the Protein 
Atlas. In normal tissue, renal tubules and glomerulus 
cells exhibited moderate to strong cytoplasmic immuno- 
reactivity. USP21 expression was lost or reduced in 
116 tumors (~62%), unchanged in 45 cases (24%) and 
increased in 25 cases (14%) (Figure 4B). Surprisingly, we 
noted that the intensity of USP21 protein down-regulation 
was greater in lower stage and lower grade tumors and that 
this difference was smaller in more advance stage/grade 
tumors (Figure 4C-4F).
DISCUSSION
Suppression of Hippo signaling results in increased 
YAP activity, which can contribute to oncogenic 
transformation in many types of human cancer. This study 
provides evidence that USP21 acts through stabilization of 
MARK kinases to limit YAP/TAZ activity. Loss of USP21 
expression would therefore lead to reduced MARK-Hippo 
signaling resulting in increased expression of oncogenic 
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YAP. The normal activity of USP21 may contribute to 
tumor suppression.
Consistent with this mechanism, we found that 
expression of USP21 protein is reduced or lost in a 
majority of human RCC tumors, compared to paired 
normal tissue from the same individual. We did not 
observe a significant correlation between USP21 protein 
expression and overall cancer survival, for the 89 paired 
samples with patient survival information. This might be 
a consequence of the sample size. However, we noted that 
USP21 is located in region 1q21 of chromosome 1, which 
is frequently amplified in human cancers. This region 
contains many oncogenes such as CREB3L4 and MDM2 
and increase in their copy number has been linked with 
worse survival for many human cancers [32–35]. The fact 
that USP21 is located in this amplified region may have 
obscured any association between USP21 expression with 
cancer survival. Indeed, we observed that the intensity of 
USP21 protein down-regulation became less profound 
in more advanced cancers, suggesting that selection for 
regional amplification might lead to a secondary increase 
in USP21 concomitant with disease progression. It is 
tempting to speculate that low USP21 may contribute to 
tumor formation early in cancer development, but that this 
effect might be obscured by secondary genetic changes 
including amplification of region 1q21.
USP21 may regulate different signaling pathways 
and its effect on oncogenic transformation may depend 
on the prevailing signaling that controls cell growth. 
A previous study showed that USP21 deubiquitylates 
receptor-interacting protein 1, a suppressor of TNF-
induced NF-KB activation. Thus, USP21 can act as a 
negative regulator of NF-KB signaling [36]. Another study 
showed that USP21 expression is upregulated in bladder 
tumors and suggested that USP21 could promote cancer 
growth and metastasis by inhibiting the ubiquitylation of 
EZH2 in bladder cancer cell lines [37]. In this study, the 
small subset of RCC tumors (14%) displayed an increased 
Figure 3: USP21 inhibition promotes oncogenic transformation in BJ and cancer cell lines. Assays for colony formation 
in soft agar. (A, B) BJT/p53kd/p16kd/RasG12V/YAPwtcells, (C) A549 lung cancer cells, (D) MDA-MB-231 breast cancer cells. Cells were 
transduced to express shRNAs against USP21 or a control. After antibiotic selection, cells were plated in soft agar for 10 days (A549 
cells), 2 weeks (BJ cells) and 3 weeks (MDA-MB-231 cells). Representative images of colonies formed from BJ cells after 2 weeks (A). 
Average colony number per well ± SD from three independent experiments of BJ (B), A549 (C) and MDA-MB-231 (D) cells. p values were 
determined using the student’s t test (2-tailed, unequal variance).
Oncotarget64101www.impactjournals.com/oncotarget
expression of USP21 as compared to their matched normal 
tissues and the diminishment of downregulated USP21 in 
higher grade or more advanced tumors might suggest that 
additional signaling regulated by USP21 contribute to 
cancer progress. In addition, we also found that USP21 
inhibition suppressed soft agar growth of metastatic breast 
cancer MDA-MB-468 cell lines (Supplementary Figure 7). 
These apparently opposite effects of USP21 in different 
cancers and cell lines suggest that the impact of USP21 
depletion may depend on the underlying pattern of genetic 
and epigenetic alterations found in different tumors and 
cellular contexts.
Figure 4: USP21 expression in kidney tumors and adjacent matched normal tissues. (A) Immunohistochemical staining of 
kidney tissues (in pairs of tumor and adjacent normal samples) with anti-USP21. (B) Plot showing histopathology scores for anti-USP21 
staining of RCC tumors and matched adjacent normal tissue. The slides were examined by experienced pathologists to confirm the tissue 
identity and assigned a score: 0 (no staining), 1 (weak staining of less than 10% of tissue), 2 (weak staining of 10–25% of tissue), 3 (weak 
to moderate staining of up to 50% tissue), 4 (moderate to strong staining of 50–75% of tissue), 5 (moderate to strong staining of more than 
75% of tissue). Data show the IHC score for the tumor minus that of adjacent normal tissue. (C, E) IHC scores for anti-USP21 staining 
of individual RCC samples separated by histological grade. Data show the average of the tumor-normal scores. * indicates a statistically 
significant difference using the Mann-Whitney test (p=0.006 in C and = 0.02 in E). (D, F) Histopathology scores for anti-USP21 staining 
of RCC samples separated by tumor stage. Data show the average of the tumor-normal scores. Student’s t-test (2-tailed, unequal variance) 
was used to determine the significance of differences among groups. * indicates p=0.002 (D) and =0.01 (F).
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MATERIALS AND METHODS
Antibodies
Antibodies to MARK2 (#9118), phospho-MARK 
activation loop (#4836) YAP/TAZ (#8418), pYAP S127 
(#4911), pYAP S397 (#13619), LATS1 (#9153), LATS2 
(#13646), pLATS1/2 Thr1079/1041 (#8654), MOB1 
(#3863), phosphor-MOB1 (Thr35, #8699), MST1 (#3682), 
phosho-MST1/2 (Thr183/180, #3681)) and Myc Tag 
(#2278) were from Cell Signaling Technology (Danvers, 
MA, USA). HA antibody (#sc-7392) was from Santa Cruz 
Biotechnology (Dallas, TX, USA). Anti-USP21, anti-
MARK1, anti-actin, HA-, and Myc-conjugated beads were 
from Sigma-Aldrich (St Louis, MO, USA).
Plasmids, siRNAs and shRNAs
8xGTIIC-luciferase was a gift from Stefano Piccolo 
(Addgene plasmid #34615). The pRL-CMV (Renilla, 
#E2261) was purchased from Promega (Madison, WI, 
USA). HA/Flag-USP21 was a gift from Wade Harper 
(Addgene plasmid # 22574). The pBabe-myc-MARK1 
expression plasmid was cloned by PCR using cDNA 
from HEK293T cells. Flag-USP21, Flag-USP21C221S 
and myc-MARK1K768A mutants were generated by PCR 
as previously described [38] and subcloned into pBabe 
expression vector. The HA-ubiquitin expression plasmid 
was a kind gift from Dr. Simon Bekker-Jensen (University 
of Copenhagen). LATS2 shRNA was described in [39]. 
USP21 siRNAs were purchased from Sigma-Aldrich. 
Details of the shRNAs sequences used to deplete USP21 
are provided in Supplmentary Table 1.
Luciferase assays
Luciferase assay to measure YAP/TAZ activity were 
performed as described (ref) using a dual luciferase kit 
(E1960, Promega).
Quantitative real-time RT-PCR
RNA extraction, cDNA synthesis and quantitative 
PCR were performed as previously described [23]. qPCR 
primer sequences are provided in Supplmentary Table 1.
Cell culture, transfection, immunoblotting, 
immunoprecipitation and ubiquitin assay
BJ fibroblast, A549, MDA-MB-231, MDA-MB-468 
and HEK293T cells were obtained from ATCC and 
cultured in DMEM (Sigma) with 10% fetal calf serum 
(HyClone) and 1% penicillin-streptomycin. HEK293T 
cells were transfected with using the Calcium phosphate 
method. Western blotting was performed as previously 
described [23]. For co-immunoprecipitation, HEK293T 
cells were pretreated overnight with 5μM MG132, 
washed once with cold PBS and lysed with PLC buffer 
[40] containing 50 mM Hepes pH 7.5, 150 mM NaCl, 
5 % Glycerol, 0.5 % Triton X-100, 1.5 mM MgCl2, 1 
mM EGTA supplemented with 20 μg/ml RNAase A, 1 
mM DTT, 1 mM Na3VO4 and protease inhibitor cocktail 
on ice for 30 minutes. Supernatant was collected after 
centrifugation and pre-cleared with proteins A/G beads 
(Santa Cruz, sc#2003). Antibodies against isotype controls, 
USP21 and MARK1 were pre-incubated with proteins 
A/G agarose for 2h before being immunoprecipitated 
with pre-cleared cell lysates overnight at 4°C. Agarose 
beads were washed 4x with PLC buffer before being 
subjected to Western blot analysis. For ubiquitin assays, 
a mixture of 5μg of myc-MARK1 expression plasmid 
and 2μg of HA-ubiquitin expression plasmid was co-
transfected with either scrambled control or USP21 
siRNA (final concentration of 50 nM) in 10-cm disc of 
HEK293T cells. 36h-transfected cells were further treated 
with MG132 5μM overnight before being harvested for 
immunoprecipitation. Cells were washed once with cold 
PBS lysed in the PLC buffer freshly supplemented with 
20mM of N-ethylmaleimide (NEM, Sigma). Pre-cleared 
cell lysate was incubated with myc antibody-conjugated 
agarose on a rotator at 4°C for 3h. Beads were washed 
4x with lysis buffer and eluted as recommended by the 
manufacturer.
Immunohistochemical analysis
Tissue arrays (KD1503, KD1504 and HKid-
CRC180Sur-01) containing 186 pairs of kidney clear 
cell carcinoma and their matched normal tissues were 
obtained from the US Biomax, Rockville, MD, USA. 
Immunochemical staining of tissue arrays was performed 
and samples were analyzed by 2 experienced pathologists 
as previously described [23].
Viral transduction and soft agar assay
Amphotropic retroviruses were made as described 
previously [41]. Supernatant from transfected Phoenix-
Ampho cells (Nordic Biosite ApS, Copenhagen, Denmark) 
was harvested at 36–48 h, snap-frozen in liquid nitrogen 
and stored in aliquots at -80°C for subsequent viral 
transductions. Cells were plated to reach 70% confluence 
when infected with viruses overnight in the presence of 
8 μg/ml of polybrene. Antibiotic selection was started 
after 36h of infection. Stable cells were plated for soft agar 
growth assay as described [1].
Statistical analyses
The Student’s t-test (2-tailed, unequal variance) was 
used to determine the significance of differences among 
conditions for luciferase assays and quantitative PCR. 
The Chi-square test was used to assess the significances 
of differences in subcellular localization of YAP.
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clear cell carcinoma).
Author contributions
THN, JMK and SMC designed the experiments 
and wrote the manuscript. THN and JMK performed the 
experiments. ACL examined the histological staining of 
RCC samples with anti-USP21. AD performed statistical 
analysis. SMC acquired funding and supervised the 
project.
ACKNOWLEDGMENTS
We would like to thank Peter Eichhorn (Cancer 
Science Institute of Singapore) for providing the USP21 
shRNAs and Simon Bekker Jensen (University of 
Copenhagen) for ubiquitin vectors and for technical 
advice. We also thank Mette Lind Holm and Birgitte 
Grønkær Toft for helping with testing RCC samples and 
histological examination and Diana Andrejeva for helping 
with bioinformatics analysis.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
FUNDING
This work was supported by grants from the Novo 
Nordisk Foundation (NNF12OC0000552) and the Neye 
foundation to SMC. The funders had no role in study 
design, data collection and analysis, decision to publish, 
or preparation of the manuscript.
REFERENCES
1. Nguyen HT, Hong X, Tan S, Chen Q, Chan L, Fivaz M, 
Cohen SM, Voorhoeve PM. Viral small T oncoproteins 
transform cells by alleviating hippo-pathway-mediated 
inhibition of the YAP proto-oncogene. Cell Rep. 2014; 
8:707–713.
2. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and 
human cancer. Nat Rev Cancer.  2013; 13: 246–257.
3. Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, 
Zhuang Z, Lonser RR. Neurofibromatosis type 2. Lancet. 
2009; 373:1974–1986.
4. Richter AM, Pfeifer GP, Dammann RH. The RASSF 
proteins in cancer; from epigenetic silencing to 
functional characterization. Biochim Biophys Acta. 2009; 
1796:114–128.
5. Bai H, Gayyed MF, Lam-Himlin DM, Klein AP, Nayar SK, 
Xu Y, Khan M, Argani P, Pan D, Anders RA. Expression 
of Yes-associated protein modulates Survivin expression 
in primary liver malignancies. Hum Pathol. 2012; 
43:1376–1385.
6. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, 
Pan D, Montgomery EA, Anders RA. Expression of Yes-
associated protein in common solid tumors. Hum Pathol. 
2008; 39:1582–1589.
7. Zender L, Spector MS, Xue W, Flemming P, Cordon-
Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, 
Mu D, Lucito R, Powers S, Lowe SW. Identification and 
validation of oncogenes in liver cancer using an integrative 
oncogenomic approach. Cell. 2006; 125:1253–1267.
8. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, 
Sgroi DC, Deng CX, Brugge JS, Haber DA. Transforming 
properties of YAP, a candidate oncogene on the 
chromosome 11q22 amplicon. Proc Natl Acad Sci U S A. 
2006; 103:12405–12410.
9. Fullenkamp CA, Hall SL, Jaber OI, Pakalniskis BL, Savage 
EC, Savage JM, Ofori-Amanfo GK, Lambertz AM, Ivins SD, 
Stipp CS, Miller BJ, Milhem MM, Tanas MR. TAZ and YAP 
are frequently activated oncoproteins in sarcomas. Oncotarget. 
2016; 7:30094–30108. doi: 10.18632/oncotarget.8979.
10. Wang L, Shi S, Guo Z, Zhang X, Han S, Yang A, Wen W, 
Zhu Q. Overexpression of YAP and TAZ is an independent 
predictor of prognosis in colorectal cancer and related to 
the proliferation and metastasis of colon cancer cells. PLoS 
One. 2013; 8:e65539.
11. Xia Y, Chang T, Wang Y, Liu Y, Li W, Li M, Fan HY. YAP 
promotes ovarian cancer cell tumorigenesis and is indicative 
of a poor prognosis for ovarian cancer patients. PLoS One. 
2014; 9:e91770.
12. Sun Z, Xu R, Li X, Ren W, Ou C, Wang Q, Zhang H, Zhang 
X, Ma J, Wang H, Li G. Prognostic value of Yes-associated 
protein 1 (YAP1) in various cancers: a meta-analysis. PLoS 
One. 2015; 10:e0135119.
13. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos 
E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, 
Karachaliou N, et al. The Hippo effector YAP promotes 
resistance to RAF- and MEK-targeted cancer therapies. Nat 
Genet. 2015; 47:250–256.
14. Kim MH, Kim J, Hong H, Lee SH, Lee JK, Jung E, Kim 
J. Actin remodeling confers BRAF inhibitor resistance to 
melanoma cells through YAP/TAZ activation. EMBO J. 
2016; 35:462–478.
15. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A 
coordinated phosphorylation by Lats and CK1 regulates 
Oncotarget64104www.impactjournals.com/oncotarget
YAP stability through SCF -TRCP. Genes Dev. 2010; 
24:72–85.
16. Liu CY, Zha ZY, Zhou X, Zhang H, Huang W, Zhao D, 
Li T, Chan SW, Lim CJ, Hong W, Zhao S, Xiong Y, Lei 
QY, Guan KL. The Hippo tumor pathway promotes TAZ 
degradation by phosphorylating a phosphodegron and 
recruiting the SCF -TrCP E3 ligase. J Biol Chem. 2010; 
285:37159–37169.
17. Hong X, Nguyen HT, Chen Q, Zhang R, Hagman Z, 
Voorhoeve PM, Cohen SM. Opposing activities of the Ras 
and Hippo pathways converge on regulation of YAP protein 
turnover. EMBO J. 2014; 33:2447–2457.
18. Lignitto L, Arcella A, Sepe M, Rinaldi L, Delle Donne 
R, Gallo A, Stefan E, Bachmann VA, Oliva MA, Tiziana 
Storlazzi C, L'Abbate A, Brunetti A, Gargiulo S, et al. 
Proteolysis of MOB1 by the ubiquitin ligase praja2 
attenuates Hippo signalling and supports glioblastoma 
growth. Nat Commun. 2013; 4:1822.
19. Wang C, An J, Zhang P, Xu C, Gao K, Wu D, Wang D, 
Yu H, Liu JO, Yu L. The Nedd4-like ubiquitin E3 ligases 
target angiomotin/p130 to ubiquitin-dependent degradation. 
Biochem J. 2012; 444:279–289.
20. Bae SJ, Kim M, Kim SH, Kwon YE, Lee JH, Kim J, Chung 
CH, Lee WJ, Seol JH. NEDD4 controls intestinal stem cell 
homeostasis by regulating the Hippo signalling pathway. 
Nat Commun. 2015; 6:6314.
21. Salah Z, Itzhaki E, Aqeilan RI. The ubiquitin E3 ligase 
ITCH enhances breast tumor progression by inhibiting 
the Hippo tumor suppressor pathway. Oncotarget. 2014; 
5:10886–10900. doi: 10.18632/oncotarget.2540.
22. Salah Z, Melino G, Aqeilan RI. Negative regulation of the 
Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to 
promote tumorigenicity. Cancer Res. 2011; 71:2010–2020.
23. Thanh Nguyen H, Andrejeva D, Gupta R, Choudhary 
C, Hong X, Eichhorn PJ, Loya AC, Cohen SM. 
Deubiquitylating enzyme USP9x regulates hippo pathway 
activity by controlling angiomotin protein turnover. Cell 
Discov. 2016; 2:16001.
24. Nguyen HT, Kugler JM, Cohen SM. DUB3 deubiquitylating 
enzymes regulate hippo pathway activity by regulating the 
stability of ITCH, LATS and AMOT proteins. PLoS One, 
2017; 12:e0169587.
25. Urbé S, Liu H, Hayes SD, Heride C, Rigden DJ, Clague MJ. 
Systematic survey of deubiquitinase localization identifies 
USP21 as a regulator of centrosome- and microtubule-
associated functions. Mol Biol Cell. 2012; 23:1095–1103.
26. Meng Z, Moroishi T, Guan KL. Mechanisms of Hippo 
pathway regulation. Genes Dev. 2016; 30:1–17.
27. Mohseni M, Sun J, Lau A, Curtis S, Goldsmith J, Fox VL, 
Wei C, Frazier M, Samson O, Wong KK, Kim C, Camargo 
FD. A genetic screen identifies an LKB1–MARK signalling 
axis controlling the Hippo–YAP pathway. Nat Cell Biol. 
2013; 16:108–117.
28. Heidary Arash E, Shiban A, Song S, Attisano L. MARK4 
inhibits Hippo signaling to promote proliferation and 
migration of breast cancer cells. EMBO Rep. 2017; 
18:420–436.
29. Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the 
human deubiquitinating enzyme interaction landscape. Cell. 
2009; 138:389–403.
30. Urbé S, Liu H, Hayes SD, Heride C, Rigden DJ, Clague MJ. 
Systematic survey of deubiquitinase localization identifies 
USP21 as a regulator of centrosome- and microtubule-
associated functions. Mol Biol Cell. 2012; 23:1095–1103.
31. Wagner SA, Beli P, Weinert BT, Nielsen ML, Cox J, Mann 
M, Choudhary C. A proteome-wide, quantitative survey of 
in vivo ubiquitylation sites reveals widespread regulatory 
roles. Mol Cell Proteomics. 2011; 10:M111.013284.
32. Chen L, Chan TH, Guan XY. Chromosome 1q21 
amplification and oncogenes in hepatocellular carcinoma. 
Acta Pharmacol Sin. 2010; 31:1165–1171.
33. Nilsson M, Meza-Zepeda LA, Mertens F, Forus A, 
Myklebost O, Mandahl N. Amplification of chromosome 1 
sequences in lipomatous tumors and other sarcomas. Int J 
Cancer. 2004; 109:363–369.
34. Shah GL, Landau H, Londono D, Devlin SM, Kosuri S, 
Lesokhin AM, Lendvai N, Hassoun H, Chung DJ, Koehne 
G, Jhanwar SC, Landgren O, Levine R, Giralt SA. Gain 
of chromosome 1q portends worse prognosis in multiple 
myeloma despite novel agent-based induction regimens 
and autologous transplantation. Leuk Lymphoma. 2016; 
58:1823–1831.
35. Chagtai T, Zill C, Dainese L, Wegert J, Savola S, Popov 
S, Mifsud W, Vujanić G, Sebire N, Le Bouc Y, Ambros 
PF, Kager L, O'Sullivan MJ, et al. Gain of 1q as a 
prognostic biomarker in Wilms Tumors (WTs) treated with 
preoperative chemotherapy in the International Society of 
Paediatric Oncology (SIOP) WT 2001 trial: a SIOP renal 
tumours biology consortium study. J Clin Oncol. 2016; 
34:3195–3203.
36. Xu G, Tan X, Wang H, Sun W, Shi Y, Burlingame S, Gu X, 
Cao G, Zhang T, Qin J, Yang J. Ubiquitin-specific peptidase 
21 inhibits tumor necrosis factor -induced nuclear factor B 
activation via binding to and deubiquitinating receptor-
interacting protein 1. J Biol Chem. 2010; 285:969–978.
37. Chen Y, Zhou B, Chen D. USP21 promotes cell proliferation 
and metastasis through suppressing EZH2 ubiquitination in 
bladder carcinoma.  Onco Targets Ther. 2017; 10:681–689.
38. Allemandou F, Nussberger J, Brunner HR, Brakch N. Rapid 
site-directed mutagenesis using two-PCR-generated DNA 
fragments reproducing the plasmid template. J Biomed 
Biotechnol. 2003; 2003:202–207.
39. Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop 
H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, 
Zlotorynski E, Yabuta N, De Vita G, et al. A genetic screen 
Oncotarget64105www.impactjournals.com/oncotarget
implicates miRNA-372 and miRNA-373 as oncogenes in 
testicular germ cell tumors. Cell. 2006; 124:1169–1181.
40. Wells CD, Fawcett JP, Traweger A, Yamanaka Y, Goudreault 
M, Elder K, Kulkarni S, Gish G, Virag C, Lim C, Colwill 
K, Starostine A, Metalnikov P, Pawson T. A Rich1/Amot 
complex regulates the Cdc42 GTPase and apical-polarity 
proteins in epithelial cells. Cell. 2006; 125:535–548.
41. Brummelkamp TR. A system for stable expression of short 
interfering RNAs in mammalian cells. Science. 2002; 
296:550–553.
